SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by AspenBio Pharma, Inc. on May 16, 2012, covering events occurring on May 11, 2012, and May 15, 2012. The registrant is a Colorado corporation headquartered in Castle Rock, CO. Note: The request metadata referenced "Riot Platforms, Inc."; however, the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. The primary financial disclosure relates to a regulatory compliance issue:
- Stockholders' Equity: The company failed to meet the Nasdaq minimum requirement of $2,500,000 in stockholders' equity as of May 15, 2012.
- Liquidity/Debt: No specific liquidity or debt metrics are disclosed in this document.
Material Changes and Events
- Nasdaq Delisting Notice: On May 15, 2012, the company received notice from Nasdaq regarding non-compliance with Rule 5550(b)(1) due to insufficient stockholders' equity. The company has 45 calendar days to submit a compliance plan. If accepted, an extension of up to 180 days may be granted. The company expects to be listed as non-compliant within five business days.
- Executive Departure: On May 11, 2012, Erik S. Miller resigned from his position as Vice President of Marketing and Business Development.
Outlook, Risks, and Management Commentary
The filing highlights the immediate risk of delisting from the Nasdaq Stock Market if the company fails to regain compliance with the minimum stockholders' equity rule. Management has not provided forward-looking financial guidance or specific details on the strategy to restore equity levels within this report. The primary contingency is the submission of a compliance plan within the 45-day window.
Investor Verification Checklist
- Verify the current stockholders' equity balance to assess the severity of the deficit against the $2.5 million threshold.
- Monitor for the submission of a compliance plan to Nasdaq within the 45-day deadline.
- Confirm the company's status on the Nasdaq list of non-compliant companies.
- Review subsequent filings for details on the replacement of the departing Vice President of Marketing and Business Development.